Shopping Cart

No products in the cart.

Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Identification of a novel biomarker for sarcopenia diagnosis using serum metabolomic analysis: a pilot study.

This pilot study compared serum metabolites in participants with and without sarcopenia. Metabolomic techniques were applied to identify serum metabolites and novel biomarkers specific to patients with sarcopenia. In accordance with AWGS2019 criteria, sarcopenia was defined as low muscle mass...
🗓️ 2024-01-12
📰 Publication: European Geriatric Medicine
Read MoreIdentification of a novel biomarker for sarcopenia diagnosis using serum metabolomic analysis: a pilot study.

Association of phasae angle dynamics with sarcopenia and activities of daily living in osteoporotic fracture patients.

This study aimed to determine whether changes in phase angle during rehabilitation are associated with clinical outcomes such as activities of daily living (ADL), skeletal muscle index (SMI), and strength in patients with osteoporotic fractures. This retrospective observational study included...
🗓️ 2024-03-15
Read MoreAssociation of phasae angle dynamics with sarcopenia and activities of daily living in osteoporotic fracture patients.

Prevalence of sarcopenia in Africa: a systematic review and meta-analysis of observational studies.

Existing literature suggests that sarcopenia is a highly prevalent condition in older people. However, most studies to date reporting data on its prevalence have been mainly carried out in Western countries, while data on sarcopenia in Africa is scarce. With...
🗓️ 2024-01-28
📰 Publication: Aging Clinical And Experimental Research
Read MorePrevalence of sarcopenia in Africa: a systematic review and meta-analysis of observational studies.

Association between Sarcopenia and Reduced Bone Mass: Is Osteosarcopenic Obesity a New Phenotype to Consider in Weight Management Settings?

Sarcopenic obesity (SO) is a frequent phenotype in people with obesity; however, it is unclear whether this links with an impaired bone status. In this study, we aimed to investigate the association between SO and low bone mass, and to...
🗓️ 2023-12-21
Read MoreAssociation between Sarcopenia and Reduced Bone Mass: Is Osteosarcopenic Obesity a New Phenotype to Consider in Weight Management Settings?

Effect of Sarcopenia on the Increase in Liver Volume and Function After Portal Vein Embolization.

Sarcopenia is associated with a decreased kinetic growth rate (KGR) of the future liver remnant (FLR) after portal vein embolization (PVE). However, little is known on the increase in FLR function (FLRF) after PVE. This study evaluated the effect of...
🗓️ 2024-02-28
📰 Publication: Cardiovascular And Interventional Radiology
Read MoreEffect of Sarcopenia on the Increase in Liver Volume and Function After Portal Vein Embolization.

Cancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.
🗓️ January 2024
📰 Publication: Clinical Nutrition
Read MoreCancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

Sarcopenia Metrics and Quality of Life Components: What Is the Link?

Sarcopenia is known to be negatively associated with quality of life in affected patients. However, the individual impacts of its metrics, i.e. muscle mass, strength, and physical performance, on patients’ overall quality of life remain to be thoroughly investigated. This pre-printed study aimed to characterise the associations between sarcopenia metrics and quality of life outcomes in community-dwelling older adults from the SOMMA (Study of Muscle, Mobility and Aging) study. Health-related quality of life was ascertained using the EQ-5D questionnaire, which measures 5 subcomponents: mobility, self-care, usual activities, pain and discomfort, as well as anxiety and depression.
Read MoreSarcopenia Metrics and Quality of Life Components: What Is the Link?

Sarcopenia and Type 2 Diabetes: A Bidirectional Relationship

Sarcopenia is characterised by age-related reductions in skeletal muscle strength, mass, and functional ability. Importantly, sarcopenia is a multifactorial condition associated with metabolic alterations, including poor glucose disposal, insulin resistance, decreased metabolic rate and, thus, type 2 diabetes (T2D). Developing non-pharmaceutical guidelines for the prevention and treatment of both diseases when they coexist is essential to optimise patient health and reduce premature mortality within this patient population. This review aimed to examine 1) the pathophysiological link between sarcopenia and T2D, and 2) lifestyle interventions with the potential to mitigate both sarcopenia and T2D.
Read MoreSarcopenia and Type 2 Diabetes: A Bidirectional Relationship

Leucine-enriched Protein Supplementation for the Pre-frail: What Are the Benefits?

It is known that one in five adults with pre-frailty progresses to frailty over a 3-year period. Low protein and energy intake, increased prevalence of multimorbidity, and a sedentary lifestyle are well-characterised drivers of sarcopenia. Consequently, they act as catalysts of older adults’ transition to frailty. In this vein, stimulating increased muscle protein synthesis through regular physical exercise and protein-enriched diet consumption is pivotal for pre-frail older adults. Current U.S. Food and Nutrition Board guidelines recommend a dietary allowance of 0.8 g/kg of protein per day for older adults. However, this amount may be insufficient for those with pre-frailty due to their low-grade inflammation, multimorbidity, and increased susceptibility to anabolic resistance. This study aimed to examine the impact of leucine-enriched protein supplementation with or without exercise on 1) physical function, 2) body composition, and 3) systemic inflammation in pre-frail older adults with a daily protein consumption of ≤1 g/kg.
Read MoreLeucine-enriched Protein Supplementation for the Pre-frail: What Are the Benefits?

GDF-15: a mediator of exercise’s link with late-life weight loss?

Ageing is often associated with appetite reduction and ensuing weight loss. Although it is known that physical activity (PA) can prevent these ageing-related processes, the exact molecular mechanisms underpinning this ability remain unknown. Recent research has highlighted the role of exerkines, i.e. proteins released during and after PA, in controlling energy metabolism. Growth differentiation factor 15 (GDF-15), a stress-signalling cytokine secreted during PA and involved in ageing, exercise, and appetite control, has emerged as a potential mediator of late-life, ageing-related weight loss. This study aimed to explore the associations between PA, GDF-15, and body weight changes in older adults enrolled in the Multidomain Alzheimer Preventive Trial over a 3-year period.
📰 Publication: Journal of Cachexia, Sarcopenia and Muscle
Read MoreGDF-15: a mediator of exercise’s link with late-life weight loss?
Age-Related Spinal Deformity: a Consequence of Sarcopenia?

Age-Related Spinal Deformity: a Consequence of Sarcopenia?

This study investigates the connection between sarcopenia and age-related spinal deformities, focusing on lumbar paravertebral muscles (PVM) quality and volume. Results show that sarcopenic patients have higher ectopic fat infiltration in PVM, contributing to spinal deformities, highlighting the importance of understanding and addressing sarcopenia in relation to spinal health.
📰 Publication: Spine 2022
Read MoreAge-Related Spinal Deformity: a Consequence of Sarcopenia?
Appetite Loss, Malnutrition, and Mortality: a Significant Association in Need of Urgent Recognition?

Appetite Loss, Malnutrition, and Mortality: a Significant Association in Need of Urgent Recognition?

This systematic literature review highlights the underrecognition of appetite loss in older adults and its association with malnutrition and mortality. The study underscores the urgent need for standardized screening and comprehensive guidelines to improve the assessment and management of appetite loss in this population.
📰 Publication: Journal of Cachexia, Sarcopenia and Muscle 2023
Read MoreAppetite Loss, Malnutrition, and Mortality: a Significant Association in Need of Urgent Recognition?
Sarcopenia and its Prognostic Value in Advanced Gastroesophageal Cancer

Sarcopenia and its Prognostic Value in Advanced Gastroesophageal Cancer

This study reveals the prognostic value of sarcopenia measurements in patients with advanced metastatic gastroesophageal cancer, showing its association with poor overall and progression-free survival. The findings highlight the importance of considering sarcopenia status alongside clinical variables for better prognostication.
Read MoreSarcopenia and its Prognostic Value in Advanced Gastroesophageal Cancer

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!